The Association of <i>ERBB2</i>-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer
Kelvin K H Bao, Leone Sutanto, Shirley S. W. Tse, Ka Man Cheung, Jeffrey Chan
Abstract
This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated with CDK4/6 inhibitors.
Topics & Concepts
Breast cancerHormone receptorCancerCancer researchInternal medicineMetastatic breast cancerKinaseOncologyMedicineCyclin-dependent kinase 4HormoneHER2 negativeEndocrinologyBiologyCell cycleCyclin-dependent kinase 2GeneticsAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysCancer Treatment and Pharmacology